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Abstract
Altered metabolism proceeding seroconversion in children progressing to Type 1 diabetes has previously been
demonstrated. We tested the hypothesis that non-obese diabetic (NOD) mice show a similarly altered metabolic profile
compared to C57BL/6 mice. Blood samples from NOD and C57BL/6 female mice was collected at 0, 1, 2, 3, 4, 5, 6, 7, 9, 11, 13
and 15 weeks and the metabolite content was analyzed using GC-MS. Based on the data of 89 identified metabolites OPLS-
DA analysis was employed to determine the most discriminative metabolites. In silico analysis of potential involved
metabolic enzymes was performed using the dbSNP data base. Already at 0 weeks NOD mice displayed a unique metabolic
signature compared to C57BL/6. A shift in the metabolism was observed for both strains the first weeks of life, a pattern that
stabilized after 5 weeks of age. Multivariate analysis revealed the most discriminative metabolites, which included inosine
and glutamic acid. In silico analysis of the genes in the involved metabolic pathways revealed several SNPs in either
regulatory or coding regions, some in previously defined insulin dependent diabetes (Idd) regions. Our result shows that NOD
mice display an altered metabolic profile that is partly resembling the previously observation made in children progressing
to Type 1 diabetes. The level of glutamic acid was one of the most discriminative metabolites in addition to several
metabolites in the TCA cycle and nucleic acid components. The in silico analysis indicated that the genes responsible for this
reside within previously defined Idd regions.
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Introduction
Type 1 diabetes is an autoimmune disease which in contrast to
the majority of other autoimmune diseases arises already at young
age [1]. The genetic contribution to the disease has been estimated
to be ,50%, including .50 involved loci [2], (www.t1dbase.org).
In addition, environmental factors such as infections, diet and
climate has been attributed as potential underlying contributors.
Although the pathogenesis process in diabetes is so far only
detectable as either the appearance of islet-specific autoantibodies
and/or the mononuclear infiltration in the islets of Langerhan’s, it
is evident that this process is preceded by other molecular and
cellular events, which in turn could be reflected by the
metabolome. In line with this it has been demonstrated that
children with genetic predisposition for T1D development and
that progress to T1D display an altered serum metabolic profile
compared to the group of non-progressors [3,4]. Specifically the
levels of succinic acid and phosphatidylcholin were reduced at
birth, and elevated levels of glutamic acid preceded seroconver-
sion, i.e. appearance of autoantibodies specific for insulin and
glutamic acid decarboxylase (GAD).
The metabolic changes in relation to time of diabetes onset have
also been studied in the congenic BB rat model [5]. An alteration
in the metabolic profile was observed in DP rats compared to DR1
and DR2 rats 1–2 weeks prior to diabetes onset, and at this time
point, based levels of 17 metabolites, it was possible to discriminate
progressors versus non-progressors. In line with the studies in
humans, phospholipids and the amino acid isoleucine was altered.
However, in the rat model it was not possible to score any
metabolic differences at earlier time points than 1–2 weeks prior to
disease onset.
The NOD mouse is another vastly used model for T1D [6]. In
this strain diabetes develops spontaneously and the pathological
process resembles in many ways T1D in humans. Mononuclear
infiltration in the Langerhans’ islets is detected already from 4–5
weeks whereas overt diabetes develops at 3–4 months of age and
onwards. T1D in NOD mice is a multigenetic disease where some
of the .30 involved loci (Idds) [7] are in direct syntenic
relationship with some of the human IDDMs. Moreover,
environmental factors also play an important role where
infections, diet and climate clearly has been demonstrated to play
a pivotal role [1]. Involvement of different immune cells subsets
has been extensively explored and although the disease is
transferable with T-cells solely [7], B-cells are without any doubt
crucial in the initiation of the pathogenesis process [8]. It is,
however, not clear how the disease in NOD mice is initiated.
Recently it was demonstrated that female NOD mice that
progress to T1D display an discrete metabolic profile compared to
genetically identical individuals that do not develop T1D [9] and
this could potentially be explained by differential microbiota in the
two groups. However, in this study metabolic alteration due to
genetic influences was not tested. In the current study we tested the
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35445hypothesis that NOD mice display an altered metabolic signature
compared to the non-diabetic C57BL/6 reference strain. In
addition we hypothesized that a potential deviation in the
metabolism, as if being a contributor to the initiation of the
pathogenic process, should be apparent already in young mice,
prior to the onset of insulitis.
Materials and Methods
Ethics statement, animals and blood sampling
NOD and C57BL/6 mice were originally obtained from
Bomholtgaard, Denmark and bred and maintained in the
transgenic animal facility (UTCF) at Umea ˚ University. Diabetes
Figure 1. Score plots from Principal Component Analysis (PCA) showing the first (horizontal) and second (vertical) component for
all models. A. 0–3 weeks; both NOD and B6 change over time and likewise display divergent metabolic profiles at each time point. The plot
accounts for 37.5% of the variation in the metabolite data. B. 4–15 weeks; the metabolic pattern has stabilized and the two strains are readily
separable. The plot accounts for 32.5% of the variation in the metabolite data. C. PCA at the chosen time points of 0 w, 3 w, 4 w, and 15 weeks
respectively; at each time points the strains are clearly different.
doi:10.1371/journal.pone.0035445.g001
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None of the mice in the study developed diabetes during the
sampling period. Experimental procedures were performed in
compliance with the relevant Swedish and Institutional laws and
guidelines and approved by the Umea ˚ research animal ethic
committee (A14-09). Blood samples were taken from individual
female mice at the time points 0 weeks (new born) through 6 weeks
(n=8 in all groups except for NOD 3 w n=7, B6 newborn, 1 w
and 5 w n=7 respectively and B6 6 w n=5). In order to obtain
sufficient blood for analysis at these early time points the animals
had to be sacrificed subsequently. From the 7–15 weeks old mice
individuals were consecutively sampled (n=8 in all groups). None
of the mice became diabetic throughout the study. After sampling
the blood was kept in room temperature for one hour and stored at
4uC over night. Clots was removed, remaining sera spun in a
microfuge at 13 000 rpm for five minutes, where after the sera was
stored in 280uC until the GC/MS analysis.
Metabolite extraction and GC-MS analysis
Extraction of metabolites from plasma was undertaken
following the protocol of A et al. This method has been shown
to produce semi-quantitative data of good linearity, making it
appropriate for comparisons across specie as well as time in this
study [10]. A detailed flow chart and protocol is provided as Text
S1 and Figure S1. In brief, an aliquot, 25 mL, of thawed serum was
added to Sarstedt safety cap tubes and 225 mL of the extraction
mixture consisting of methanol:water (9:1) containing 11 isotopi-
cally labeled internal standards were added. The mixture was
shaken for 2 min at 30 Hz and stored in an ice-bath for 2 h before
centrifugation for 10 min at 4uC and14000 rpm. 200 mL of the
supernatant were evaporated to in GC-MS-vials.
The samples were derivatized using methoxyamine and
MSTFA as described by A et al. and GC-MS analyses were
carried out according to the same protocol.
Data Processing GC-MS
All non-processed MS-files from the metabolic analysis were
exported from the ChromaTOF software in NetCDF format to R
(version 2.10.1) in which all data pre-treatment procedures, such
as base-line correction chromatogram alignment, data compres-
sion and Hierarchical Multivariate Curve Resolution (H-MCR)
were performed using custom scripts as described by Jonsson et al.
[11]. All manual integrations were performed using in-house R
scripts. The data processing protocols resulted in peak areas for the
derivatized metabolites and corresponding mass spectra.
Metabolite libraries, metabolite identification and
quantification
The metabolites were identified by comparison of retention
indices and mass spectra with data in commercial, as well as in-
house, retention indexes and mass spectra libraries using NIST
MS Search 2.0 (National Institute of Standards and Technology,
2001). The data processing of the GC-MS data using the H-MCR
script resulted in initial datasets. All variables were checked
manually and variables originating from internal standards and
analytical or processing artifacts excluded.
Figure 2. Heat map showing metabolites (that is significantly
(p,0.05) different (if labeled in color) in NOD compared to B6
mice. Compounds within the defined classes display similar pattern.
The plot is sorted according to compound classes.
doi:10.1371/journal.pone.0035445.g002
Metabolomics of Pre-Diabetic NOD Mouse
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35445The dataset was normalized using the 11 added internal
standards; a non-centered principal component analysis (PCA)
model was built on the basis of the intensity of selected ions
originating from the internal standard compounds and all
metabolite intensities was divided by the first component from
this model [12].
Statistical analysis
In order to identify trends in the metabolite data metabolite
concentration fold changes were calculated for NOD compared to
B6 at each time point. This was done by dividing the average
concentration in the NOD group with the average concentration
in the B6 group. In cases where the fold change was below 1 it was
replaced with the negative inverse value for clarity. To obtain a
clear overview of the data fold changes was plotted for all time
points where the difference was found statistically significant
according to two-sided Student’s t-tests for samples with equal
variance (p=0.05).
The combination of metabolites that provided the optimal
discrimination between NOD and B6 mice was found using
Orthogonal Projections to Latent Structures-Discriminant Analy-
sis (OPLS-DA) on unit variance scaled data [13–15]. OPLS-DA is
a multivariate classification technique that is used for predicting
groupings for observations and for characterizing the groups. B6
was set the value zero and NOD the value one, using a dummy
matrix. By using 7-fold cross-validation [16] and optimizing the
prediction results for models discriminating the two genotypes
using backwards variable selection [17] at the time points 0, 3, 4, 5
and 15 weeks the optimal combination of metabolites for
describing the differences between NOD and B6. These time
points were judged as the most crucial based on the previous
analyses.
Analysis of genetic differences between B6 and NOD in
relation to metabolic data
The pathways involved in the metabolism of selected metab-
olites were collected from the Kyoto Encyclopedia of Genes and
Genomes or KEGGs pathway database for mice (http://www.
genome.jp/kegg). The metabolic pathways were selected based on
metabolomics data and are the pathways where the largest
metabolic differences between NOD and B6 were observed. The
extent of the pathways was defined by the availability of
metabolomics data, i.e. pathways were extended as far as possible
with the available data. All enzymes present in a metabolic
pathway were examined. Occurrence of the enzymes in Idd
regions was analyzed using the web resource from www.T1Dbase.
org. SNPs in these enzymes were collected from the Mouse
Phenome Database using the mouse SNP wizard (http://
phenome.jax.org/db/q?rtn=snps/wiz1) listing polymorphisms
between the NOD/ShiLtJ and the control C57BL/6J strains.
Any SNPs present in the 59 upstream or 39 downstream regions
were also collected by including 2000 bps on either ends in the
search criteria. Non-synonymous SNPs were analyzed for their
effect on change of sequence and function using SIFT at http://
sift.jcvi.org/. All the analysis was carried out based on build-37 of
Entrez Genome View, which is being updated as new SNPs are
identified.
Figure 3. Backward variable selection was used to find the metabolites that were most discriminative between the stains. Box-
Whisker-plots show the prediction of stain by the OPLS model with the best predictive ability at five different time points. Values close to zero
indicate that the individual was predicted as B6 and values close to one that it was predicted as NOD. The metabolites included in the respective
models are designated below.
doi:10.1371/journal.pone.0035445.g003
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NOD and B6 mice display discrete metabolic signatures
Individual serum samples from NOD and B6 mice (0–15 weeks,
n=184) were analyzed by GC-MS. Based on the levels of 89
identified metabolites an initial overview of the data was obtained
by employing Principal Component Analysis (PCA). PCA is an
unsupervised statistical technique that summarizes multivariate
data in a smaller number of latent variables [18]. This allows
identification and visualization of groupings, trends and outliers in
the data. A metabolic shift in both strains was observed during the
first 0–3 weeks (Figure 1A), a pattern that was stabilized after 4
weeks (Figure 1B). Notably, comparing NOD and B6 mice, the
two strains could clearly be distinguished already at 0 weeks
(Figure 1C), as well at later time points (Figure 1D–F).
To obtain an overview of the individual metabolites that were
significantly different between the two strains we calculated fold
changes for all metabolites at all time points (Figure 2). Blue and
red color indicates that significantly higher respectively lower
concentrations were found in NOD compared to B6 mice. The
metabolites in the plot were sorted according to compound classes
in order to depict general trends in the dataset. We observed that
similar compounds showed similar behavior over time, i.e. natural
amino acids were generally lower in NOD compared to B6, until
four weeks where a general shift to an increased level was found.
This shift was caused by a general increase in of amino acids in the
week 4 NOD mice compared to week 3. In B6 amino acid levels
were generally constant or slightly decreasing from week 3 to 4
(Table S1).
Figure 4. Metabolic pathways possibly responsible for the differences observed in NOD and B6 mice. Metabolite concentrations at
weeks 0, 3, 4, 5 and 15 are indicated with colors. Red indicates significantly increased in NOD, blue indicates significantly increased in B6 and white
indicates no significant difference. Enzymes involved in metabolism are also show in the plot. Red text indicates that the gene is in Idd region and
bold, italic text indicates SNPs differentiating NOD and B6 mice. A. Metabolism around the TCA cycle with glutamic acid and glutamine. B. Metabolism
of nucleic acid compounds.
doi:10.1371/journal.pone.0035445.g004
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TCA cycle intermediates and this was reversed at week four where
four of these compounds (citric acid, fumaric acid, malic acid and
alpha-ketoglutaric acid) showed a large increase in B6 but not in
NOD (see Text S1, Table S1, Figures S1 and S2). These new
levels were maintained until 15 weeks of age with four of these
compounds showed a significant decrease in NOD relative to B6.
In addition from four weeks of age NOD had lower levels of most
measured free fatty acids; the notable exception being arachidonic
acid which from week seven was increased. We also observed that
methyl-inositol and pseudouridine differentiated the stains at all
ages by being consistently increased in NOD compared to B6.
Table 1. Genetic variation in the enzymes involved in metabolic pathways of interest.
Name Gene/E.C Number Idd
59 UTR
SNP
Non Synonymous
Exon
SNP(Dangerous/
Tolerated)
Intron
SNP
39 UTR
SNP
Glutamine synthetase Glul/6.3.1.2 Idd5.4b/Idd5.4
Glutaminase Gls/3.5.1.2 2
Glutamate dehydrogenase Glud1/1.4.1.3
4-aminobutyrate aminotransferase Abat/2.6.1.19
Glutamate oxaloacetate transaminase 1 Got1,2/2.6.1.1 14 1
L-amino acid oxidase 1 Lao1/1.4.3.2 2 1 (0/1) 2
Glutamic acid decarboxylase 1 Gad1/4.1.1.15 12 5
Argininosuccinate synthetase 1 Ass1/6.3.4.5 5
Adenylosuccinate synthase like 1 Adssl1/6.3.4.4
Adenylosuccinate lyase Adsl/4.3.2.2
Argininosuccinate lyase Asl/4.3.2.1
Ureidopropionase Upb1/3.5.1.6 1 (0/1) 42
Dihydropyrimidinase Dpys/3.5.2.2 41 4 7 3
Dihydropyrimidine dehydrogenase Dpyd/1.3.1.2 33
Uridine phosphorylase Upp1/2.4.2.3
Hypoxyxanthine guanine
phosphoribosyl transferase
Hprt/2.4.2.8 1
Adenosine monphosphate deaminase 1/2/3 Ampd1,2,3/3.5.4.6 1,2-Idd18.2/3-Idd27 1(Ampd1)
87(Ampd3)
7
(Ampd3)
Purine nucleoside phosphorylase Pnp/2.4.2.1 1
Xanthine dehydrogenase/oxidase Xdh/1.17.1.4/1.17.3.2 3 2 (1/1) 66
Adenosine deaminase Ada/3.5.4.4 3
Adenosine kinase Adk/2.7.1.20 3* 339
ecto-59-nucleotidase/CD73 Nt5e/3.1.3.5 Idd 2 59
Deoxycytidine kinase Dck/2.7.1.74
Ectonucleoside triphosphate
diphosphohydrolase 1/CD39
Entpd1/3.6.1.5 2
Ectonucleoside triphosphate
diphosphohydrolase (adenosinetriphosphatase)
Entpd2/3.6.1.3 2 (0/2) 3 1
Nucleoside-diphosphate kinase Nme7/2.7.4.6 14
Isocitrate dehydrogenase ldh3a,3b,3g/1.1.1.41 Idd2/Idd13 2
Succinate-Coenzyme A ligase Suclg1/Suclg2/Sucla2 6.2.1.4 79 2
Succinate dehydrogenase complex Sdha,b,c,d/1.3.5.1 a-Idd14/d-Idd2 3 (Sdha)1(Sdhb)
3(Sdhc)
2 (0/2) 15(Sdha)
50(Sdhb)
52(Sdhc)
3*
Fumarate hydratase 1 Fh1/4.2.1.2 3
Malate dehydrogenase 1 Mdh1,2/1.1.1.37 19
3-hydroxy-3-mehtylglutaryl-CoenzymeA reductase Hmgcr/1.1.1.34 Idd14
Pannexin (Panx 3- imp in cartilage) Panx1,2,3 Panx3-Idd27 12
P2X purinoreceptor P2rx1,2,3,4,5,6,7 20 1 (0/1) 68
P2Y purinergic receptor P2ry1,2,4,6,10,12,13,14 P2ry2,6-Idd27 81 9 (P2ry2)
10(P2ry6)
7(P2ry12)
*Defined locus in regulatory region.
doi:10.1371/journal.pone.0035445.t001
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glutamic acid
As the PCA analysis and statistical tests of metabolite differences
indicated major changes in the metabolic profiles the first weeks of
age (i.e. weeks 3–5) we performed a more thorough analysis for
these time points, also including the 0 and 15 weeks of age time
points as reference time points. To identify the metabolites
discriminating the two stains the most at the five time points,
multivariate models with reduced number of metabolites was
tested until separation of the mouse strains started deteriorating.
The model that provided the optimal separation between the two
stains was determined, and the including metabolites in this model
is presented in Figure 3 and Figure S2. Metabolites belonging to
the nucleic acid group (i.e. uracil, pseudouridin, inosine and
hypoxanthine) as well as to the TCA cycle and related amino acids
(i.e. alpha-ketoglutaric acid and glutamic acid) were among the
most disciminative metabolites.
Pathway analysis reveals potential responsible enzymes
and targeted receptors
The observed metabolic differences between NOD and B6 were
likely due to alterations in the enzymes participating in the
metabolism. Therefore, we analyzed, by using the KEGG data
base, which metabolic enzymes and pathways that could be
involved in metabolism of the most discriminative metabolites
presented in Figure 3. As seen in Figure 4 the most characteristic
differences in metabolism between B6 and NOD could be traced
to two main pathways; metabolism around the TCA cycle with
glutamic acid and glutamine (Figure 4A), and metabolism of
nucleic acid compounds (Figure 4A and B). Based on this analysis
we selected 32 enzymes and three receptors involved in the two
pathways. The corresponding genes for these proteins were
analyzed for any potential genetic differences between NOD and
B6. The positioning and sequences of the corresponding genes in
NOD and B6 were retrieved from the dbSNP database [19]. Our
search yielded 1 274 SNPs out of which 9 SNPs were present in
exons, 71 in the 59,3 9 UTRs and the remaining 1 194 in the
intron regions (Table 1).
Out of the 32 enzymes, five enzymes were found to be present
in previously defined Idd regions (Table 1). Eight non synonymous
exon SNPs (one in L-amino acid oxidase1, one in ureidopropio-
nase, two in xanthine dehydrogenase, two in succinate dehydro-
genase, two in ectonucleoside triphosphate diphosphohydrolase)
resulted in amino acid substitutions, although only one SNPs
(Xdh-rs29522348) was predicted by SIFT to be damaging utilizing
both orthologue and homologue alignment. Of the 43 UTR SNPs
in the enzymes, six SNPs (Adk-rs30494865, rs47796269,
rs30728355, Sdhc-rs31555970, rs31555968, rs30909739) were
found to be in the regulatory regions based on the dbSNP
annotation.
In addition, the differences in the nucleic acid related molecules
prompted us to investigate potential cell surface expressed
receptors for these molecules. Three purinergic receptors, i.e.
pannexin, P2X purinoreceptor and P2Y purinergic receptor were
analyzed whereof two of the three receptors were found to be
present in Idd regions (Table 1). When analyzed for the presence of
SNPs, we found 28 located in UTR regions, one in exons (P2rx-
rs13467733) and 116 SNPs in the intron regions.
Discussion
It has previously been demonstrated that children with genetic
predisposition for T1D development and that progressed to T1D
display an altered serum metabolic profile compared to the group
of non-progressors [3]. In this study we employed the NOD mouse
with the hypothesis that this strain would display similar metabolic
alteration as the T1D progressors, with the purpose that this model
could give insight in the underlying molecular cause of these
alterations. We found that NOD mice display a substantial altered
metabolism compared to B6 already as a newborn and this
difference was maintained throughout the 15 weeks analyzed.
In general the amino acid levels were slightly decreased in NOD
prior to weaning, where after there was a general shift towards an
increased level. It has been shown that the level of amino acids in
the blood could be an indication of the status of glucose
metabolism, i.e. higher levels of amino acids would indicate an
increasing degree of catabolism [20]. Indeed the NOD mouse
display higher levels of glucose already at birth and a reciprocal
pattern of glucose levels to the amino acids was noted after
weaning, supporting this notion. In addition, the level of isoleucine
and valine were increased in NOD already in newborns (0 w) as
well as right after weaning (3 w). The BCAAs have been shown to
promote insulin secretion [21] which in turn could have an
negative impact on the b-cells, i.e. excessive insulin secretion could
lead to b-cell death [22].
Interestingly, in accordance with the Oresic study [3] we
observed that glutamic acid was among the metabolites that
discriminated the two strains the most. In addition to the increased
level of glutamic acid a decreased level of glutamine was also
observed as well. Both glutamine, and in particular glutamate,
have effects on the immune system although the exact mechanism
is still to be revealed [23]. Oresic et al hypothesized that initially
anti-GAD antibodies may appear as a result of defective
metabolism. In NOD mice anti-GAD antibodies appear between
3–4 weeks [24] in line with our observed increased level of
glutamic acid. However, in contrast to the human study, no
change of the glutamic acid levels in NOD relative to B6 was
observed after this time point. In the analysis of metabolic
pathways involving glutamic acid and related metabolites of the
TCA cycle, i.e. alpha-ketoglutaric acid, we found that several
enzymes, whereof some were located in previously defined Idd
regions, displayed SNPs. There were a total of 1 078 SNPs in the
introns of the analyzed enzymes which potentially could be critical
for splicing either directly by altering donor, acceptor or branch
sites. The efficiency of splicing could also be affected by intron
SNPs due to splicing enhancer or silencer motifs alternatively by
changing the secondary structure of the RNA. In addition, intron
SNPs have been shown to affect enzyme activity [25], as well as a
affect the expression levels of involved genes [26,27]. A few non-
synonomous exon SNPs were also found and the effect of these
remains to be investigated. In general, the in silico genetic
polymorphism analysis showed that several of the genes that are
involved in metabolism of compounds highlighted both in this and
in the Oresic study, are present in Idd regions. Although this does
not prove involvement or the exact mechanism of involvement, it,
however, supports a possible link between the observed metabolic
changes and the potential responsible gene. This provides an
interesting area for further studies in order to understand the
mechanism behind the observed metabolic differences and their
relation to development of T1D. Indeed, more detailed functional
studies of these enzymes are desired.
One of the most striking differences that we observed was the
difference in the nucleic acid related molecules. Recently it was
found that NOD mice express increased levels of ADA promoting
autoreactive T cell activation and diabetes development [28]. We
have found that enzymes involved in ATP and adenosine
metabolism have both non synonymous as well as intron SNPs.
This can lead to potentially faulty metabolism of ATP and
Metabolomics of Pre-Diabetic NOD Mouse
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metabolite of adenosine degradation was found. This can be the
result of increased expression of ADA or a defect in ADA and
ecto-nucleotidase enzymes. In addition, non-synonymous SNPs
(rs28232063, rs28232059) were found in the ecto-nucleosidase,
Entpd2, which is responsible for breakdown of ATP. A defect in
this enzyme could lead to increased amounts of available ATP, an
immune activator, causing increased cell activation and possibly
autoreactive T cell activation. When we examined potential
receptors we found three that also displayed some polymorphism
comparing NOD and B6. The combination of both ligand and
receptor alterations that in themselves may not seem that
substantial but in combination could promote disease is plausible.
Indeed, the effect of the P2X7 purinergic receptor has recently
been described to act in combination with CD38 in promotion of
T1D in the NOD mouse [29].
Another interesting observation was that methyl-inositol was
markedly increased in NOD throughout the study. In the BB rat
increased amounts of a methyl-inositol, identified as ribitol, was
also singled out as one of the most discriminative for development
markers for onset of diabetes [5]. This compound is clearly of
exogenous origin and thus this demonstrate that there were not
only metabolic differences but also differences in ability to ingest
and metabolize exogenous compounds between animals that
develop T1D and those that do not. Also campesterol, which is a
plant sterol, was taken up differently between the stains with NOD
displaying lower levels than B6. This also resembles our previous
observation in the BB rat, where sitosterol and other sterol
compounds were found decreased before diabetes onset [5].
The possibility to predict T1D progressors at the pre-diabetic
stage is of importance as prevention, compared to reversion, of
T1D has proven much more efficient, in particular in the NOD
mouse where a large number of interventions has been described,
as reviewed in [30]. If and how the pathways identified in this
study contribute to the development of T1D cannot be proven
conclusively based on our data. The results do, however, indicate
that NOD mice display similar metabolic perturbations to human
T1D progressors. Thus, the combination of metabolic profiling
studies including definition of the underlying molecular mecha-
nisms, and intervention studies such as feeding of certain
metabolites, alternatively pharmaceutical inhibition of certain
enzymes, could be tested in NOD mice. The metabolic
consequences as well as effects on T1D development could hence
be linked and contribute to our understanding of the pathogenesis
leading to T1D development.
Supporting Information
Text S1 Detailed protocol.
(DOC)
Figure S1 Experimental design for metabolite identifi-
cation.
(DOC)
Figure S2 The measured values of the compounds
found most significantly changed between B6 and NOD
mice at time points 0, 3, 4, 5 and 15 weeks as accounted
for in Figure 3.
(DOC)
Table S1 Fold change of metabolites.
(DOC)
Acknowledgments
The authors would like to acknowledge Krister Lundgren and Inga-Britt
Carlsson (Umea ˚ University and Swedish University of Agriculture
Sciences) for technical assistance in the mass spec analysis.
Author Contributions
Conceived and designed the experiments: KL JT TM. Performed the
experiments: KL RM VB. Analyzed the data: KL RM VB JT. Wrote the
paper: KL RM VB JT TM.
References
1. Vehik K, Dabelea D (2011) The changing epidemiology of type 1 diabetes: why
is it going through the roof? Diabetes Metab Res Rev 27: 3–13.
2. Todd JA (2010) Etiology of type 1 diabetes. Immunity 32: 457–467.
3. Oresic M, Simell S, Sysi-Aho M, Nanto-Salonen K, Seppanen-Laakso T, et al.
(2008) Dysregulation of lipid and amino acid metabolism precedes islet
autoimmunity in children who later progress to type 1 diabetes. J Exp Med
205: 2975–2984.
4. Pflueger M, Seppanen-Laakso T, Suortti T, Hyotylainen T, Achenbach P, et al.
(2011) Age- and islet autoimmunity-associated differences in amino Acid and
lipid metabolites in children at risk for type 1 diabetes. Diabetes 60: 2740–2747.
5. A ˚kesson L, Trygg J, Fuller J, Madsen R, Gabrielsson J, et al. (2011) Serum
metabolite signature predicts the acute onset of diabetes in spontaneously
diabetic congenic BB rats. Metabolomics. pp 1–11.
6. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, et al. (1980)
Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29: 1–13.
7. Driver JP, Serreze DV, Chen YG (2011) Mouse models for the study of
autoimmune type 1 diabetes: a NOD to similarities and differences to human
disease. Semin Immunopathol 33: 67–87.
8. Forsgren S, Andersson A, Hillo ¨rn V, Soderstrom A, Holmberg D (1991)
Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese
diabetic (NOD) mouse. Scand J Immunol 34: 445–451.
9. Sysi-Aho M, Ermolov A, Gopalacharyulu PV, Tripathi A, Seppanen-Laakso T,
et al. (2011) Metabolic regulation in progression to autoimmune diabetes. PLoS
Comput Biol 7: e1002257.
10. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, et al. (2005) Extraction and
GC/MS analysis of the human blood plasma metabolome. Anal Chem 77:
8086–8094.
11. Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, et al. (2005) High-throughput
data analysis for detecting and identifying differences between samples in GC/
MS-based metabolomic analyses. Anal Chem 77: 5635–5642.
12. Redestig H, Fukushima A, Stenlund H, Moritz T, Arita M, et al. (2009)
Compensation for systematic cross-contribution improves normalization of mass
spectrometry based metabolomics data. Anal Chem 81: 7974–7980.
13. Bylesjo ¨ M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006)
OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA
classification. Journal of Chemometrics 20: 341–351.
14. Trygg J, Wold S (2002) Orthogonal projections to latent structures (O-PLS).
Journal of Chemometrics 16: 119–128.
15. Trygg J, Holmes E, Lundstedt T (2007) Chemometrics in metabonomics.
J Proteome Res 6: 469–479.
16. Wold S (1978) Cross-Validatory Estimation of the Number of Components in
Factor and Principal Components Models. . Technometrics 20: 397–405.
17. Andersen CM, Bro R (2010) Variable selection in regression—a tutorial. Journal
of Chemometrics 24: 728–737.
18. Jollife IT (2002) Principal Component Analysis New York Springer-Verlag.
19. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the
NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.
20. Guyton AC, Hall JE (2011) Medical Physiology.
21. Floyd JC, Jr., Fajans SS, Knopf RF, Conn JW (1963) Evidence That Insulin
Release Is the Mechanism for Experimentally Induced Leucine Hypoglycemia
in Man. J Clin Invest 42: 1714–1719.
22. Fonseca SG, Urano F, Burcin M, Gromada J (2010) Stress hypERactivation in
the beta-cell. Islets 2: 1–9.
23. Newsholme P (2001) Why is L-glutamine metabolism important to cells of the
immune system in health, postinjury, surgery or infection? J Nutr 131:
2515S–2522S; discussion 2523S-2514S.
24. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, et al. (1993) Immune
response to glutamic acid decarboxylase correlates with insulitis in non-obese
diabetic mice. Nature 366: 72–75.
25. Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, et al. (2005) OAS1
splice site polymorphism controlling antiviral enzyme activity influences
susceptibility to type 1 diabetes. Diabetes 54: 1588–1591.
26. Duan J, Sanders AR, Molen JE, Martinolich L, Mowry BJ, et al. (2003)
Polymorphisms in the 59-untranslated region of the human serotonin receptor
1B (HTR1B) gene affect gene expression. Mol Psychiatry 8: 901–910.
Metabolomics of Pre-Diabetic NOD Mouse
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e3544527. Miller GM, Madras BK (2002) Polymorphisms in the 39-untranslated region of
human and monkey dopamine transporter genes affect reporter gene expression.
Mol Psychiatry 7: 44–55.
28. Ghaemi Oskouie F, Shameli A, Yang A, Desrosiers MD, Mucsi AD, et al. (2011)
High levels of adenosine deaminase on dendritic cells promote autoreactive T
cell activation and diabetes in nonobese diabetic mice. J Immunol 186:
6798–6806.
29. Chen YG, Scheuplein F, Driver JP, Hewes AA, Reifsnyder PC, et al. (2011)
Testing the role of P2X(7) receptors in the development of type 1 diabetes in
nonobese diabetic mice. J Immunol 186: 4278–4284.
30. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, et al. (2005)
A comprehensive review of interventions in the NOD mouse and implications
for translation. Immunity 23: 115–126.
Metabolomics of Pre-Diabetic NOD Mouse
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35445